The Hormones in Dosage (excluding contraceptives and antibiotics) market in the UK saw a declining trend from 2024 onwards, starting from $39.98 per capita and projected to reach $26 by 2028. This represents an average annual contraction (CAGR) of approximately 10.2% over the five-year forecast period. The year-on-year decrease highlights consecutive declines as the market shrinks, indicating diminished demand or external pressures causing reduction in market size. These changes reflect a potential market saturation or shifts in healthcare practices and consumption patterns.
Future trends to watch for include:
- Technological advancements in hormone therapies.
- Healthcare policy changes impacting access and pricing.
- Emerging competitors or innovative products entering the market.
- Shift in patient demographics influencing demand.
